Highlights & Updates
05
Oncode Accelerator: Highlights & Updates
In this overview, we present a snapshot of our progress, scientific updates from consortium partners, media attention and major milestones from the first months of Oncode Accelerator.
Animal-free and affordable alternative for growing organoids
Researchers from Hubrecht Institute, UMC Utrecht, the Princess Máxima Center and Oncode Institute have developed an exciting new tool for scientists working with organoid technology.
Read more
AlphaBridge: validating AI-powered predictions for cancer biologists
A new platform from the group of Prof. Perrakis at the Netherlands Cancer Institute is already helping scientists understand which T-cell receptors can elicit immune responses for tumour antigens.
Read more
Unraveling the complexity of the tumor microenvironment
Prof. Sjoerd van der Burg’s team (LUMC) used advanced technologies to identify features of the tumor micro-environment associated with cancer vaccine success.
Read more
Cancer vaccine facility opens at the Princess Máxima Center for pediatric oncology
With the opening of their lead finding facility, an important milestone within national partnership Oncode Accelerator has been reached.
Read more
With the support of several Oncode Accelerator collaborators and other experts, FAST created a renewed and expanded guidebook for developing ATMPs in the Netherlands.
Read more
At the end of 2024, OncoZON signed a letter of intent to participate in this automated data flow.
Read more
Oncode Accelerator was incorporated
into the longstanding Memorandum of Understanding between Oncode Institute and Cancer Research Horizons.
Read more
New protocol for generating and engineering human fetal brain organoids
Scientists at the Princess Máxima Center for pediatric oncology published a new protocol for establishing, maintaining, and characterizing human fetal brain organoids - valuable in vitro models for the developing human brain that closely mimick in vivo tissue.
Read more
A new and versatile tool for researchers in oncology and beyond
The group of Prof. Gerard van Westen (Leiden University) introduced QSPRpred, a new open-source, modular, and customizable tool to help scientists predict the behavior of a molecule based on its molecular structure.
Read more
Oncode Accelerator has launched its first two Demonstrator Projects
Oncode Accelerator has launched its first two Demonstrator Projects, marking a significant milestone for the program. These projects focus on developing therapeutic vaccines that train the immune system to recognize and destroy cancer cells. This innovative approach has the potential to improve survival rates for cancer patients of all ages by providing new treatment options.
Training the Immune System
Pediatric Sarcomas
Mapping cancer cell metabolism with patient-derived tumoroids
A new study from the group of Dr. Jarno Drost (Princess Máxima Center for pediatric oncology, Oncode Institute) shows that metabolic signatures of pediatric kidney tumors are preserved in patient-derived tumor organoids, or tumoroids. This research underscores the value of tumoroids in cancer research and paves the way for improved therapies.
Read more
Understanding systems often mis-regulated in cancer
Polycomb repressive complexes (PRCs) are a diverse group of protein complexes that are commonly mis-regulated in cancer. A deeper understanding of their biology can potentially inform development of future therapies. A recent publication from the group of Prof. Michiel Vermeulen (Radboud University) provided new insights into Polycomb biology.
Read more
Share this article
Next Article